Business
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period").
About this update from Hbm Holdings Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period").","length":394,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Harbour BioMed)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Harbour BioMed)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":159,"url":"https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QANxnzzeBFHKxcqoWHourA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a","width":400,"height":159}},"href":"https://mma.prnewswire.com/media/1096360/HB_for_email_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$68 million (equivalent to approximately HK$532 million) and US$74 million (equivalent to approximately HK$579 million).","length":271,"tagName":"p"},{"type":"text","content":"The anticipated increase in profit is primarily attributable to:","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continuing strategic partnerships with leading global pharmaceutical companies, including the global strategic collaboration with AstraZeneca.- The Company has received gross proceeds totaling approximately US$175 million from the allotment and issuance of the subscription shares, as well as partial upfront, milestone, and option exercise fees.","length":359,"tagName":"p"}]},{"val":[{"type":"text","content":"Newly secured out-licensing and collaboration agreements for innovative products, which contributed significantly to revenue during the Reporting Period and are evolving into a normalized revenue stream of the Company.","length":218,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":577,"olType":false},{"type":"text","content":"Dr. Jingsong Wang, Founder, Ch...